Victory Capital Management Inc. Buys 4,229 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Victory Capital Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,909 shares of the biopharmaceutical company’s stock after acquiring an additional 4,229 shares during the quarter. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $11,801,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ALNY. Price T Rowe Associates Inc. MD grew its stake in shares of Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after buying an additional 201,784 shares during the last quarter. Capital International Investors grew its stake in shares of Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after buying an additional 64,560 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock valued at $137,238,000 after purchasing an additional 32,966 shares during the period. Finally, TD Asset Management Inc boosted its holdings in shares of Alnylam Pharmaceuticals by 6.0% in the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after purchasing an additional 27,592 shares during the period. 92.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research reports. Bank of America boosted their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday. Finally, TD Cowen upped their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $248.79 on Thursday. The business’s 50-day moving average is $273.83 and its two-hundred day moving average is $236.76. The company has a market capitalization of $32.09 billion, a P/E ratio of -94.96 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.